go-v.orgdoi

Aflibercept ophthalmic solution: drug development and clinical uses

Michael W. Stewart · Clinical Investigation · 2013

  • DOI 10.4155/cli.13.94
  • Publisher OMICS Publishing Group
  • Type article
  • Issued 2013

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Clinical Investigation · OMICS Publishing Group · article · 2013

Abstract

The recent adoption of drugs that inhibit the actions of VEGF has dramatically changed ophthalmology. The intravitreal injection of potent anti-VEGF medications, particularly bevacizumab and ranibizumab, has become standard-of-care for the treatment of the most common blinding diseases – exudative age-related macular degeneration and diabetic macular edema. The introduction of aflibercept, a high binding affinity fusion protein, gives physicians another valuable tool for the treatment of these conditions.

The VIEW 1 and 2 trials showed that monthly and bimonthly aflibercept was equivalent to monthly ranibizumab for the treatment of age-related macular degeneration, and the COPERNICUS and GALILEO trials showed that aflibercept was far superior to sham injections for the treatment of macular edema due to central retinal vein occlusions. Ongoing trials are investigating the efficacy of aflibercept for the treatment of edema due to diabetic retinopathy, branch retinal vein occlusions and myopic choroidal neov...

Open the resolved locator · 10.4155/cli.13.94

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-20 03:47 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://doi.org/10.4155/cli.13.94
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.